71 related articles for article (PubMed ID: 20562667)
1. Rituximab for thyroid eye disease.
Silkiss RZ; Reier A; Coleman M; Lauer SA
Ophthalmic Plast Reconstr Surg; 2010; 26(5):310-4. PubMed ID: 20562667
[TBL] [Abstract][Full Text] [Related]
2. Potential role of IGF-1R in the interaction between orbital fibroblasts and B lymphocytes: an implication for B lymphocyte depletion in the active inflammatory phase of thyroid-associated ophthalmopathy.
Wang R; Song D; Zhong Y; Li H
BMC Immunol; 2024 May; 25(1):31. PubMed ID: 38734625
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy.
Burak KW; Swain MG; Santodomingo-Garzon T; Lee SS; Urbanski SJ; Aspinall AI; Coffin CS; Myers RP
Can J Gastroenterol; 2013; 27(5):273-80. PubMed ID: 23712302
[TBL] [Abstract][Full Text] [Related]
4. Alemtuzumab-induced thyroid eye disease successfully treated with a single low dose of rituximab.
Muller I; Maioli S; Armenti M; Porcaro L; Currò N; Iofrida E; Pignataro L; Manso J; Mian C; Geginat J; Salvi M
Eur Thyroid J; 2024 Apr; 13(2):. PubMed ID: 38471303
[TBL] [Abstract][Full Text] [Related]
5. B-lymphocyte depletion with rituximab and β-cell function: two-year results.
Pescovitz MD; Greenbaum CJ; Bundy B; Becker DJ; Gitelman SE; Goland R; Gottlieb PA; Marks JB; Moran A; Raskin P; Rodriguez H; Schatz DA; Wherrett DK; Wilson DM; Krischer JP; Skyler JS;
Diabetes Care; 2014 Feb; 37(2):453-9. PubMed ID: 24026563
[TBL] [Abstract][Full Text] [Related]
6. Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysis.
Wang C; Ning Q; Jin K; Xie J; Ye J
BMC Ophthalmol; 2018 Feb; 18(1):46. PubMed ID: 29452583
[TBL] [Abstract][Full Text] [Related]
7. Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease.
Kahaly GJ; Dolman PJ; Wolf J; Giers BC; Elflein HM; Jain AP; Srinivasan A; Hadjiiski L; Jordan D; Bradley EA; Stan MN; Eckstein A; Pitz S; Vorländer C; Wester ST; Nguyen J; Tucker N; Sales-Sanz M; Feldon SE; Nelson CC; Hardy I; Abia-Serrano M; Tedeschi P; Janes JM; Xu J; Vue P; Macias WL; Douglas RS
J Clin Endocrinol Metab; 2023 Nov; 108(12):3122-3134. PubMed ID: 37390454
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum thyroid stimulating immunoglobulin linked to failure of first-line intravenous methylprednisolone monotherapy in moderate-to-severe thyroid eye disease.
Zloto O; Rosset A; Priel A; Landau-Prat D; Cukierman-Yaffe T; Shavit R; Agmon-Levin N; Ben Simon GJ; Sagiv O
Eye (Lond); 2024 Mar; 38(4):687-690. PubMed ID: 37821543
[TBL] [Abstract][Full Text] [Related]
9. Inter-observer Variability of Clinical Activity Score: Assessments in Patients With Thyroid Eye Disease.
Perros P; Žarković M; Pearce SH; Razvi S; Kolli H; Dickinson AJ
Am J Ophthalmol; 2023 Aug; 252():94-100. PubMed ID: 37028695
[TBL] [Abstract][Full Text] [Related]
10. Determinants of the duration of B-cell depletion after rituximab in a pediatric population.
Affes R; Lapeyraque AL; Laroche C; Labrosse R; Cambier A; Demers E; Flahault A
Nephrol Dial Transplant; 2023 Dec; 39(1):159-162. PubMed ID: 37433571
[No Abstract] [Full Text] [Related]
11. Rituximab for thyroid-associated ophthalmopathy.
Minakaran N; Ezra DG
Cochrane Database Syst Rev; 2013 May; (5):CD009226. PubMed ID: 23728689
[TBL] [Abstract][Full Text] [Related]
12. B-cell targeted therapy with rituximab for thyroid eye disease: closer to the clinic.
Shen S; Chan A; Sfikakis PP; Hsiu Ling AL; Detorakis ET; Boboridis KG; Mavrikakis I
Surv Ophthalmol; 2013; 58(3):252-65. PubMed ID: 23253433
[TBL] [Abstract][Full Text] [Related]
13. Teprotumumab for Thyroid-Associated Ophthalmopathy.
Smith TJ; Kahaly GJ; Ezra DG; Fleming JC; Dailey RA; Tang RA; Harris GJ; Antonelli A; Salvi M; Goldberg RA; Gigantelli JW; Couch SM; Shriver EM; Hayek BR; Hink EM; Woodward RM; Gabriel K; Magni G; Douglas RS
N Engl J Med; 2017 May; 376(18):1748-1761. PubMed ID: 28467880
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.
Salvi M; Vannucchi G; Currò N; Campi I; Covelli D; Dazzi D; Simonetta S; Guastella C; Pignataro L; Avignone S; Beck-Peccoz P
J Clin Endocrinol Metab; 2015 Feb; 100(2):422-31. PubMed ID: 25494967
[TBL] [Abstract][Full Text] [Related]
15. Potential utility of rituximab for Graves' orbitopathy.
Salvi M; Vannucchi G; Beck-Peccoz P
J Clin Endocrinol Metab; 2013 Nov; 98(11):4291-9. PubMed ID: 24009135
[TBL] [Abstract][Full Text] [Related]
16. Early low-dose rituximab for active thyroid eye disease: An effective and well-tolerated treatment.
Insull EA; Sipkova Z; David J; Turner HE; Norris JH
Clin Endocrinol (Oxf); 2019 Jul; 91(1):179-186. PubMed ID: 30864162
[TBL] [Abstract][Full Text] [Related]
17. Observation study of using a small dose of rituximab treatment for thyroid-associated ophthalmopathy in seven Chinese patients: One pilot study.
Wang Y; Hu H; Chen L; Zhang H; Yang T; Xu X; Chen H
Front Endocrinol (Lausanne); 2022; 13():1079852. PubMed ID: 36743915
[TBL] [Abstract][Full Text] [Related]
18. Future Projections in Thyroid Eye Disease.
Barbesino G; Salvi M; Freitag SK
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S47-S56. PubMed ID: 36346684
[TBL] [Abstract][Full Text] [Related]
19. Teprotumumab (Tepezza) for Thyroid Eye Disease.
Couch SM
Mo Med; 2022; 119(1):36-41. PubMed ID: 36033157
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for thyroid-associated ophthalmopathy.
Kang S; Hamed Azzam S; Minakaran N; Ezra DG
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD009226. PubMed ID: 35709102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
